Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Exploring the companies and themes that make up this emerging and exciting new sector
Awakn Life Sciences Signs MOU with Maps
Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
Better Life Pharma reports encouraging pre-clinical results for its non-hallucinogenic psychedelic analog.
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder
Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.
Psychedelics Convergence in 2022: Crisis Meets Opportunity
The Mental Health Crisis spirals. Psychedelic medicine advances. In 2022, "crisis" meets "opportunity".
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada's SAP.
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Health Canada’s SAP Amendments: A Game-Changer For Psychedelic Medicine In Canada?
On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.